home / stock / ipsef / ipsef quote
Last: | $131.1968 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $131.1968 |
High: | $0 |
Low: | $0 |
Volume: | 494 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$131.1968 | $0 | $131.1968 | $0 | $0 | 494 | 07-12-2024 |
$131.1968 | $0 | $131.1968 | $0 | $0 | 265 | 07-08-2024 |
$131.1968 | $0 | $131.1968 | $0 | $0 | 8 | 07-01-2024 |
$131.1968 | $0 | $131.1968 | $0 | $0 | 439 | 06-14-2024 |
$131.1968 | $0 | $131.1968 | $0 | $0 | 1 | 06-10-2024 |
$131.1968 | $0 | $131.1968 | $0 | $0 | 2,236 | 05-29-2024 |
$132.5 | $0 | $132.5 | $0 | $0 | 9 | 05-28-2024 |
$132.5 | $132.5 | $132.5 | $132.5 | $132.5 | 171 | 05-21-2024 |
$117.6 | $0 | $117.6 | $0 | $0 | 8 | 05-15-2024 |
$117.6 | $0 | $117.6 | $0 | $0 | 62 | 04-24-2024 |
$117.6 | $0 | $117.6 | $0 | $0 | 1,908 | 04-17-2024 |
$117.6 | $0 | $117.6 | $0 | $0 | 15 | 04-03-2024 |
$117.6 | $117.6 | $117.6 | $117.6 | $117.6 | 100 | 03-14-2024 |
$110.3565 | $110.3565 | $110.3565 | $110.3565 | $110.3565 | 1,559 | 03-01-2024 |
$110.5243 | $110.5243 | $110.5243 | $110.5243 | $110.5243 | 1,054 | 02-29-2024 |
$111.5 | $111.5 | $111.5 | $111.5 | $111.5 | 100 | 02-21-2024 |
$113.25 | $0 | $113.25 | $0 | $0 | 15 | 02-20-2024 |
$113.25 | $0 | $113.25 | $0 | $0 | 22 | 02-14-2024 |
$113.25 | $112.21 | $113.25 | $113.25 | $112.21 | 200 | 02-13-2024 |
$117.25 | $0 | $117.25 | $0 | $0 | 1 | 02-12-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified throug...
Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreemen...
Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholan...